The LIFE Trial
Losartan Intervention For Endpoint reduction in hypertension study (LIFE)
Presented at the American College of Cardiology
51st Annual Scientific Session
Atlanta, GA
Dr Bj?rn Dahl?f
for the LIFE Investigators
LIFE: Major clinical end points in patients with ISH
RR=risk ratio
Kjeldsen SE et al. JAMA 2002;288:1491-98.
LIFE: Major clinical end points in patients without ISH
RR=risk ratio
Kjeldsen SE et al. JAMA 2002;288:1491-98.
Patients with hypertension (blood pressure 160-200/ 95-115 mm Hg)
and left ventricular hypertrophy
Atenolol
Beta-blocker
Dose titrated to BP <140/90 mm Hg
(n=4,588)
Losartan
Angiotensin II antagonist
Dose titrated to BP <140/90 mm Hg
(n=4,605)
Followed for >4 years - Mean follow-up 4.8 years
Cardiovascular death, MI, stroke
LIFE: Study Design
Losartan
Atenolol
P=0.021
Composite of CV Death / MI / Stroke
LIFE: Primary Composite Endpoint
Adjusted Hazard Ratio = 0.87
Rate 23.8/1,000
patient yrs
Rate 27.9/1,000
patient yrs
n=508
n=588
P=0.206
P=0.491
Cardiovascular Death
Myocardial Infarction
P=0.001
Stroke
LIFE: Individual Endpoint Results
Adjusted HR 0.89
Adjusted HR 1.07
Adjusted HR 0.75
Losartan
Atenolol
Losartan
Atenolol
Losartan
Atenolol
Losartan
Atenolol
P=0.001
LIFE: New-onset diabetes
Adjusted Hazard Ratio = 0.75
Rate 13.0/1,000
patient yrs
Rate 17.4/1,000
patient yrs
n=241
n=319